贝伐单抗联合XELOX方案治疗晚期结直肠癌的临床观察被引量：21

导出

摘要目的:观察贝伐单抗联合XELOX方案治疗转移性结直肠癌的临床疗效与安全性。方法:回顾性分析我院2009年1月至2011年8月收治的经病理学确诊的晚期结直肠癌病例74例,其中研究组34例(S组)接受贝伐单抗联合XELOX方案(奥沙利铂+卡培他滨)治疗,对照组40例(X组)只采用XELOX方案治疗。比较2组临床疗效和安全性。结果:近期疗效比较,实验组与对照组缓解率差异无统计学意义(RR=23.53%、22.50%,P>0.05),而疾病控制率DCR差异有统计学意义(85.29%、65.00%,P<0.05),说明贝伐方面联合XELOX方案对晚期结肠癌的疾病控制方面优于只用XELOX方案,远期疗效比较中,两组TTP分别为9.5个月、6.8个月,中位总生存时间为17.15个月、14.34个月,差异均有统计学意义(P<0.05)。两组患者不良反应发生率没有明显差别,联合贝伐组的高血压发生率为32%,主要表现为舒张压升高,相应治疗均缓解。结论:贝伐单抗联合XELOX化疗方案较单用XELOX治疗晚期结肠癌疗效显著。不良反应无明显增加,患者可以耐受。

作者房智慧马会芳张凯张伟杰王留兴

机构地区郑州大学第一附属医院肿瘤一科

出处《实用医学杂志》 CAS 北大核心 2013年第23期3928-3930,共3页 The Journal of Practical Medicine

关键词肠肿瘤贝伐单抗 XELOX方案靶向治疗

分类号 R735.3 [医药卫生—肿瘤]

引文网络
相关文献

参考文献8

1Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX vs FOLFOX- 4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results? [J]. Br J Cancer, 2011, 105(1) :58-64.
2Haydon A. Adjuvant chemotherapy in colon cancer: what is the evidence? [J]. Intern Med J, 2003.33: 119-124.
3黄党生,黄文辉,刘旭华.短期XELOX方案在Ⅲ期结肠癌术后辅助化疗中的作用[J].实用医学杂志,2012,28(11):1838-1839. 被引量：7
4杨冬阳,黎莹,刘建化,江韦韦,马冬.转移性结直肠癌化疗控制后卡培他滨维持治疗分析[J].实用医学杂志,2013,29(8):1299-1302. 被引量：20
5刁畅,程若川,张建明,魏晓平,苏艳军,刘其雨,许建彪.卡培他滨联合奥沙利铂辅助化疗方案治疗Ⅲ期结直肠癌的临床观察[J].中华肿瘤杂志,2008,30(2):147-150. 被引量：19
6罗永忠,欧阳周.XELOX与FOLFOX6方案一线治疗晚期结直肠癌的近期疗效及不良反应比较[J].现代肿瘤医学,2010,18(1):125-127. 被引量：27
7Rocha J A. Bevacizumab in combination with irinotecan, 5- fluorouracil and leucovorin given as first-line treatment of metastatic eolorectal cancer [J]. Anticancer Drugs, 2011,22 (Suppl 2) : S9-S13.
8Doi T, Boku N, Kato K, et al. Phase Ⅰ/Ⅱ Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer [ J ]. Jpn J Clin Oncol, 2010,40 (10) : 913- 920.

二级参考文献30

1林锋,张华.卡培他滨在Ⅲ期结肠癌辅助性化疗中的研究[J].循证医学,2006,6(5):281-284. 被引量：1
2De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5 fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol, 1988, 24: 1499- 1503.
3QUASAR Collaborative Group.Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as an adjuvant chemotherapy for colorectal cancer: a randomized trial. Lancet, 2000, 356:1276.
4Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin ) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer, 2006, 94 : 969-975.
5Macdonald JS. Adjuvant therapy of colon cancer. Ca Cancer J Clin, 1999, 49:202-219.
6Haydon A. Adjuvant chemotherapy in colon cancer: what is the evidence? Intern Med J, 2003, 33:119-124.
7Saris CP, Van de Vaart PJ, Rietbroek RC, et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis, 1996, 17:2763-2769.
8Cassidy J, Tabemero J, Twelves C, et al. XELOX ( capecitabine plus oxaliplatin ): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol, 2004, 22:2084-2091.
9Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase Ⅲ trail conducted in patients with advanced colorectal carcinoma. Eur J Cancer, 2001,37:597-604.
10Diaz Rubio E, Evans TR, Tabemero J, et al. Capecitabine (Xeloda) in combination with oxaliplatin : a phase I , dose - escalation study in patients with advanced or metastatic solid tumors [ J ]. Ann Oncol, 2002,13 (4) :558 - 565.